Cleveland BioLabs   Report issue

For profit Phase 1 Phase 2
Founded: Cleveland OH United States (2003)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2006
NCT00417274
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cleveland BioLabs, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

Key: Cleveland BioLabs (3) Acquired (1)

cblb612 (1 trial)

entolimod (3 trials)

naltrexone (revia) (1 trial)

quinacrine (2 trials)

Drugs in Phase 1 Trials (1)

cisplatin (platinol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Verrucous (Phase 1)

Colorectal Neoplasms (Phase 2)

Laryngeal Diseases (Phase 1)

Laryngeal Neoplasms (Phase 1)

Mucositis (Phase 1)

Nasopharyngeal Carcinoma (Phase 1)

Neutropenia (Phase 2)

Oropharyngeal Neoplasms (Phase 1)

Paranasal Sinus Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Tongue Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5